Immucell reports preliminary Q4 revenue $7.6M

Reports preliminary FY25 revenue $27.6M. “Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges,” commented Olivier te Boekhorst, president and CEO of ImmuCell (ICCC). “This was one of our highest sales quarters ever, without tailwinds from catching up on backorders. Our international business showed a decline, largely due to order timing. We are highly encouraged by the strong growth of our Tri-Shield product line, which reflects the migration from Dual-Force products and the acquisition of new dairy and beef customers seeking protection for their calves.”